Selective serotonin-reuptake inhibitor-induced movement disorders.
about
The non-motor syndrome of primary dystonia: clinical and pathophysiological implicationsSSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystoniaA critical review of akathisia, and its possible association with suicidal behaviour.Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.Serotonin syndrome and other serotonergic disorders.Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression.Restless legs syndrome and functional limitations among American elders in the Health and Retirement Study.Neurobiological mechanisms involved in sleep bruxism.Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives.Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies.Sleep and psychiatry.Depression in Parkinson's disease: conceptual issues and clinical challenges.Dose-dependent rapid-onset akathisia with aripiprazole in patients with schizoaffective disorder.Serotonin excites fast-spiking interneurons in the striatum.Acute Dystonia After Single Dose of BupropionCircuits Regulating Pleasure and Happiness-Mechanisms of Depression.The complex role of the serotonin transporter in adult neurogenesis and neuroplasticity. A critical review.Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review.Do SSRI Antidepressants Increase The Risk of Extrapyramidal Side Effects In Patients Taking Antipsychotics?Depression and Parkinson's disease: a conceptual challenge.Extrapyramidal Reactions Associated with Serotonergic Antidepressants.Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction.Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism.Antidepressant Fluoxetine Modulates the In Vitro Inhibitory Activity of Buffalo Brain Cystatin: A Thermodynamic Study Using UV and Fluorescence Techniques.Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John's Wort.Citalopram-induced hyponatraemia and parkinsonism: potentially fatal side-effects not to be missed.Selective serotonin reuptake inhibitors for aggressive behavior in patients with dementia after head injury.Selective decrease in central nervous system serotonin turnover in children with dopa-nonresponsive dystonia.Effect of cadmium on 24-h variations in hypothalamic dopamine and serotonin metabolism in adult male rats.Antidepressant-selective gynecomastia.Orofacial dyskinesia associated with the use of levofloxacin.Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone.Melatonin treatment of shoulder-and-neck dyskinesia possibly related to fluoxetine treatment.On the pharmacotherapy of sleep bruxism: placebo-controlled polysomnographic and psychometric studies with clonazepam.Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach.Association of genetic, psychological and behavioral factors with sleep bruxism in a Japanese population.Acute extrapyramidal syndrome induced by escitalopram: a case report.A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease.
P2860
Q27012793-30A566C5-A7E4-4258-A785-8BEB463A4912Q28373136-BA41C590-5468-415D-9240-E6BDF5C85364Q31116050-8DDF6E3E-676F-4A13-A995-A22F959B4031Q33587032-223D1E8D-8B38-4FAA-8988-81D6902E9381Q33799525-0C968D99-548C-48E3-9ADD-10B9DA9972ADQ33967265-9EFC96A4-B6FF-4367-AD8D-31A750DA98BFQ34182008-BE1BE8D6-71CA-4C30-8B9C-7EAAF111D1A7Q34352746-7513D5D8-E93F-4E23-8819-40B4688CEE91Q34533926-C75B9E30-A3AD-4CAD-A188-7C8CD9672B46Q34643816-4D5A080D-DA07-429D-91C7-B279E7B58942Q34677278-730D210C-5E3F-4E5C-A3E0-E84EDEF2597BQ35236650-4A225D8A-5279-4C5D-894D-7025391143C5Q35863400-A2D4461E-8642-43D6-80DA-C3CD5B8A932DQ37165585-BDAD9BA5-26A9-495B-AA6E-97955E7C8A7FQ37226165-D7BFC5D1-2BB2-46E5-A2B9-C2277BA12D3EQ37315855-7F7BC519-5E00-4FDB-AAFF-82EBF86BE6B0Q37405040-D33F6A6A-C58F-45CB-AB1F-DB0F5D29219CQ37992701-D3BEFCA3-326D-4880-8431-5E1FA58EB9D2Q38265929-2B8CDFFA-23FA-466D-A5FD-5CC7343BE5C9Q38285606-8EB6617B-E7D7-49B8-83B7-A7385EB3F775Q38434302-828BFD58-DBA5-4D9B-9AB1-E8A7DFB9D706Q38549206-9A664EF3-252F-427A-8303-5D45178FF068Q40589244-9893B3D9-3565-460B-9575-FA7131A91CADQ41249072-4B0AC710-3DC0-4C28-B46E-957FAB56CCEFQ42187506-B32C7735-8B78-4A0A-9843-53E93FF67675Q42958186-9CBBE1A3-2363-44DE-B540-1DE1A54E62A0Q43035180-71BE6382-7795-42C6-90C2-C70E985B1E7BQ43580202-69661BEE-597C-4E1B-88F4-DB548EA224E2Q44042009-3F5D16C6-46AD-442B-AE59-E1A1D977C325Q44334455-80F34DC8-D426-42B3-9E0B-05D857AA50C2Q45955839-0408EACE-214D-40EE-B08F-56456509A384Q46064422-AEF259F8-A61E-4F32-851E-E86A9AB632E4Q46098814-6E76FA45-B83D-4405-A92A-69871ADB091CQ46156997-9C1A95CE-11DF-41CF-AA52-100759FEAC2DQ46508754-87C1FA2D-F7A6-48BA-95B2-497885FEC524Q46724727-485F6B7E-DD5D-4166-B7AB-F1250710002CQ46736590-0ECD827B-CEDB-44D0-90E8-27D408CD574AQ48246924-AAB1AB4E-E833-48F9-AB30-291023E3EDEFQ48249610-15BD46A3-B492-4858-93D1-430BF2661E4BQ48372101-7B9B65E4-8505-4907-B7EF-481EE152F0FB
P2860
Selective serotonin-reuptake inhibitor-induced movement disorders.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Selective serotonin-reuptake inhibitor-induced movement disorders.
@en
Selective serotonin-reuptake inhibitor-induced movement disorders.
@nl
type
label
Selective serotonin-reuptake inhibitor-induced movement disorders.
@en
Selective serotonin-reuptake inhibitor-induced movement disorders.
@nl
altLabel
Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders
@en
prefLabel
Selective serotonin-reuptake inhibitor-induced movement disorders.
@en
Selective serotonin-reuptake inhibitor-induced movement disorders.
@nl
P2860
P356
P1476
Selective serotonin-reuptake inhibitor-induced movement disorders.
@en
P2093
P2860
P304
P356
10.1345/APH.17302
P407
P577
1998-06-01T00:00:00Z